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Abstract
Background: We investigated the prevalence of human papillomavirus (HPV) infection and associated behavioural
risk factors in men-who-have-sex-with-men (MSM) attending a clinical service in Cape Town, South Africa.
Methods: MSM were enrolled at the Ivan Toms Centre for Men’s Health in Cape Town. A psychosocial and sexual
behavioral risk questionnaire was completed for each participant and urine, oro-pharyngeal and anal swabs were
collected for HPV testing using the Linear Array HPV Genotyping Test. Logistic regression analyses were performed
to determine sexual risk factors associated with HPV infection at the three anatomical sites.
Results: The median age of all 200 participants was 32 years (IQR 26-39.5), of which 31.0 % were black, 31.5 %
mixed race/coloured and 35.5 % white. The majority of the participants (73.0 %) had completed high school, 42.0 %
had a tertiary level qualification and 69.0 % were employed. HPV genotypes were detected in 72.8 % [95 % CI: 65.
9–79.0 %], 11.5 % [95 % CI: 7.4–16.8 %] and 15.3 % [95 % CI: 10.5–21.2 %] of anal, oro-pharyngeal and urine
specimens, respectively. Prevalence of high-risk (HR)-HPV types was 57.6 % [95 % CI: 50.3–64.7 %] in anal samples,
7.5 % [95 % CI: 4.3–12.1 %] in oro-pharyngeal samples and 7.9 % [95 % CI: 4.5–12.7 %] in urine, with HPV-16 being
the most common HR-HPV type detected at all sites. HPV-6/11/16/18 was detected in 40.3 % [95 % CI: 33.3–47.6 %],
4.5 % [95 % CI: 2.1–8.4 %] and 3.2 % [95 % CI: 1.2–6.8 %] of anal, oro-pharyngeal and urine samples, respectively.
Multiple HPV types were more common in the anal canal of MSM while single HPV types constituted the majority
of HPV infections in the oropharynx and urine. Among the 88 MSM (44.0 %) that were HIV positive, 91.8 % [95 %
CI: 83.8–96.6 %] had an anal HPV infection, 81.2 % [95 % CI: 71.2–88.8 %] had anal HR-HPV and 85.9 % [95 %
CI: 76.6–92.5 %] had multiple anal HPV types. Having sex with men only, engaging in group sex in lifetime,
living with HIV and practising receptive anal intercourse were the only factors independently associated with
having any anal HPV infection.
Conclusions: Anal HPV infections were common among MSM in Cape Town with the highest HPV burden
among HIV co-infected MSM, men who have sex with men only and those that practiced receptive anal
intercourse. Behavioural intervention strategies and the possible roll-out of HPV vaccines among all boys are
urgently needed to address the high prevalence of HPV and HIV co-infections among MSM in South Africa.
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Background
Human papillomavirus (HPV) is the most common
sexually transmitted viral infection worldwide and is as-
sociated with occurrence of warts (condylomas) and a
variety of cancers in both men and women [1]. The out-
come of HPV infection depends on the specific HPV
type/s present and can range from asymptomatic infec-
tion to severe squamous cell malignancies. Low-risk
HPV types (such as types 6 and 11) are associated with
anogenital warts and mild dysplasia, while high-risk
types (such as 16 and 18) are associated with high-grade
dysplasia and cancers of the cervix, vulva, vagina, ur-
ethra, penis, anus and oropharynx [1]. HPV is an inde-
pendent risk factor for the acquisition of HIV [2]. HIV
infection is also associated with an increased risk of ac-
quiring new HPV infections and a reduction in the rate
of HPV clearance [3]. South Africa has one of the high-
est HIV prevalence rates globally with an estimated
prevalence of 12.2 % in the general population in 2012
[4]. HIV is especially prevalent among men-who-have-
sex-with-men (MSM), with estimated prevalence rates of
22.3 %, 26.8 % and 48.2 % in Cape Town, Johannesburg
and Durban, respectively [5]. Unprotected receptive anal
intercourse is up to sixteen times more likely to transmit
HIV than unprotected vaginal sex, placing MSM at
higher risk of acquiring and transmitting HIV [6]. A
meta-analysis of 53 studies reported HPV co-infection in
89 % - 93 % of HIV-infected MSM [7].
HPV infection in men is an important concern due to
its association with anal, urethral, penile and oro-
pharyngeal cancers. In South Africa, relatively little is
known about the incidence rates of these cancers in
men, and although these cancers are less common than
cervical cancer, their association with HPV infection
make them amenable to similar preventative measures
as those for cervical cancer. The risk of developing in-
vasive anal cancer was 17 times higher among MSM
than in men-who-have-sex-with-women (MSW) and
the risk doubled in HIV-infected MSM [8]. A number
of studies reported anal HPV prevalence rates of 30–70 %
in HIV-negative MSM and 71–100 % in HIV-positive
MSM [9–12]. Oral HPV infection is less common in
adults than anogenital HPV infection but is still strongly
associated with HIV infection, high-risk sexual practices,
especially engaging in oro-genital sex and having a high
number of sexual partners [13, 14]. HPV can also be found
in the urinary tract, indicating HPV infection in either
the distal or proximal urethra, prostate and/or urinary
bladder [15]. There are currently three HPV vaccines
available that were designed to prevent HPV-associated
cancer to certain HR-HPV genotypes. These HPV vaccines
include the bivalent Cervarix® HPV vaccine (GSK
Aspen) (targeting HPV types 16 and 18), the quad-
rivalent Gardasil® HPV vaccine (MSD) (targeting HPV
types 6, 11, 16 and 18) as well as the 9-valent Gardasil®
9 HPV vaccine (MSD) (targeting HPV types 6, 11, 16,
18, 31, 33, 45, 52 and 58).
Epidemiological research has remained very limited
among the MSM population in South Africa and as a re-
sult there are currently no HPV prevalence data for
MSM. Due to high HIV prevalence rates among MSM
in South Africa, this group has been identified by the
South African Department of Health for targeted health-
care interventions and HIV prevention programs [16].
This study will therefore aim to investigate the preva-
lence of HPV genotypes at different anatomical sites
(anus, oropharynx and urine) in a sample of 200 MSM
seeking care at a dedicated men’s clinic in Cape Town,
South Africa.
Methods
Population and sample selection
This study is a secondary analysis of data collected dur-
ing a cross-sectional study of symptomatic and asymp-
tomatic STIs among MSM in Cape Town, South Africa
[17]. A convenience sample of 200 sequential MSM were
enrolled by Health4Men (Anova Health Institute) at the
Ivan Toms Centre for Men’s Health (ITCMH) in Cape
Town during 2011 and 2012. These MSM were mostly
asymptomatic (71.0 %) for STIs and attended the
ITCMH for HIV, sexual health and/or mental health
care and for commodities such as condoms and lubri-
cants. The inclusion criteria for study participation in-
cluded being 18 years of age or older, having sex with
other men within one year prior to recruitment, under-
standing the study procedures, risks and benefits and
willingness to give informed consent. Study participants
attended two study-related visits two weeks apart. Dur-
ing the first visit participants were assessed for STI
symptoms and examined for STI and HIV-related clin-
ical conditions. All participants completed a researcher
administered study questionnaire and provided a self-
collected urine specimen and clinician collected rectal
and oro-pharyngeal swab. These specimens were tested
for Neisseria gonorrhoeae and Chlamydia trachomatis
using the RNA-based Aptima Combo 2 assay (Hologic-
Gen-Probe, San Diego, CA, USA.) and stored at −70 °C
for HPV testing. At the follow-up visit, results were
relayed to all participants and diagnosed conditions were
treated according to the South African Department of
Health’s first-line comprehensive management and con-
trol of STIs protocol [18]. All 200 participants gave per-
mission for their specimens to be used for future
research. Ethical approvals for this study were obtained
from the Human Research Ethics Committee (Medical)
of the University of the Witwatersrand [protocol
M120454] and the Bioethics Department at the Univer-
sity of Cape Town [protocol 419/2011].
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Psychosocial and sexual behavioural data collection
Socio-demographic and sexual behavior characteristics
were collected by designated study staff for the primary
study through personal interviews using a standardized
questionnaire. Circumcision status was confirmed dur-
ing clinical examination. A sexual partner matrix (SPM)
for the last 10 sexual encounters in the past 12 months
(or less if the participant had less than 10 sexual en-
counters in the past 12 months) was completed for each
participant. The SPM recorded the gender of each part-
ner and condom use during sexual practices that in-
cluded receptive and insertive anal intercourse, oral sex
and oro-anal sex. Vaginal intercourse was recorded for
men who had sexual encounters with female partners in
the past 12 months.
HPV detection and genotyping
HPV testing was performed at the STI Section, Centre
for HIV and STIs, National Institute for Communicable
Diseases (NICD), in Johannesburg. Three archived speci-
mens for each of the 200 enrolled MSM participants
were analysed, which included a first-void urine speci-
men, an oro-pharyngeal swab and an anal swab, which
were all previously stored at −70 °C at the STI Section,
Centre for HIV and STIs, NICD.
Genomic DNA was extracted from urine and swab
specimens using the MagNAPure Compact Automated
DNA Extractor (Roche) and used for HPV genotyping.
The Linear Array (LA) HPV Genotyping Test (Roche
Molecular Systems, Inc., Branchburg, NJ, USA) was used
to determine the HPV genotype distribution in these 600
specimens. The LA test amplified the target HPV DNA
for 37 anogenital HPV genotypes, which included 24 low
risk HPV types (6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64,
66, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39 and
CP6108) and 13 high risk HPV types (16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59 and 68). HPV-52 was only re-
corded positive in the absence of HPV types 33, 35 and 58
due to the combined probe used for these 4 types in the
LA assay. The β-globin gene was amplified as a control
for cell adequacy, extraction and amplification. Samples
with a negative β-globin result and a positive HPV DNA
result were considered valid and adequate for analyses.
Detection of HIV and other STIs
Laboratory detection of HIV, syphilis, gonorrhea and chla-
mydia infection at the urethral, anal and oro-pharyngeal
sites were previously determined for the primary study
[17]. Syphilis testing was done on site using the SD Bioline
rapid syphilis test and HIV serostatus was determined
using both the SD Bioline HIV 1/2 3.0 test (Standard
Diagnostics, Korea) and the Alere Determine HIV-1/2 kit
(Alere Medical, Japan). Specimens were previously ana-
lysed for gonorrheal and chlamydial infection at the
STI Section, NICD, using the Aptima 2 Combo assay
(Hologic-Gen-Probe, San Diego, CA, USA.).
Data confidentiality
Individual specimens and questionnaire data were delinked
from all personal identifiers and each participant was
assigned with a unique random HPV study number to
ensure anonymity. There were no documents in existence
linking original study numbers with HPV study numbers.
The HPV genotyping results obtained were therefore not
relayed to any patients and the results were only used for
research purposes.
Variables and definitions
The main outcome variables consisted of type-specific
HPV prevalence, any HPV type, HR-HPV types and
multiple HPV types. A participant was considered to
have a HR-HPV infection if he tested positive for one or
more HR- HPV genotypes, irrespective of the participant
being co-infected with one or more LR-HPV genotypes.
Multiple HPV was defined in participants with two or
more HR or LR HPV genotypes. Socio-demographic
variables of interest included age, gender, ethnicity,
dwelling location, level of education, job status and in-
come. For the purpose of this study MSM consisted of
MSM not having sex with women (MSM only) and men
who had sex with both men and women (MSMW). Add-
itional sexual behaviours included last sex with men and
women, number of male and female partners in the past
12 months, having a main partner, sex at sex-on-site
venues in past 12 months, sex with a partner met on the
internet in past 12 months, engaging in group sex in
past 12 months and lifetime, sharing sex toys, participat-
ing in transactional sex, sex while under the influence of
alcohol and drugs, lubrication used during sex and
having an STI diagnosed in the past 12 months.
Statistical analyses
HPV prevalence and questionnaire data were entered
and analysed using both Epi Info version 7 (USDHHS,
Centers for Disease Control and Prevention) and STATA
SE version 14.0 (Stata Corporation, College Station,
Texas, USA). Descriptive statistics included frequency
tables for categorical variables such as level of education,
HR-HPV and multiple HPV and summary measures i.e.
mean and standard deviation (SD) or median and inter-
quartile range (IQR) for continuous variables such as
age. Factors associated with HPV infection, comparing
differences between MSM only and MSMW and differ-
ences between HIV-positive and HIV-negative partici-
pants were assessed with Pearson chi-square test and
Fisher’s exact test for categorical variables and Stu-
dent’s t-test for continuous variables. Factors with a
p-value of ≤0.05 in the univariate logistic regression
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analyses were included in the multiple logistic regression
model to determine possible associations with outcome
variables. The HPV outcome variables included HPV
prevalence rates in this selected study population for any
HPV, HR-HPV and multiple HPV at the 3 anatomical sites
and their 95 % confidence intervals (CI); crude odds ratios
(COR) and adjusted odds ratios (AOR) and its 95 % CI
were calculated.
Results
Demographic and behavioural characteristics
Baseline characteristics, sexual behaviour and STI risks
for the 200 participants have been published [17].
Briefly, the median age of all 200 participants was
32 years (IQR 26–39.5) with three-quarters (150) under
40 years of age. A total of fifteen participants (7.5 %)
identified as transgender women (TGW; male to female).
All three major South African racial groups were equally
represented with 62 (31.0 %) black, 63 (31.5 %) mixed
race/coloured and 71 (35.5 %) white participants. Baseline
and sexual behavioural characteristics of men who have sex
with men only (MSM only) and men who have sex with
men and women (MSMW) are summarised in Table 1.
The majority of MSM participants (155; 77.5 %) indi-
cated that they had sex with men only while 45 (22.5 %)
had sex with both men and women in the preceding
12 months. More than a third of all participants (77;
38.5 %), reported transactional sex (paid and/or received
money for sex) in the past year. Significantly more
MSMW reported participating in transactional sex in
the past year (p < 0.001) and having had sex while under
the influence of drugs in their lifetime (p = 0.004). More
than half (52.3 %) of all MSM only participants were
HIV positive while only 15.6 % of MSMW had an HIV
infection (p < 0.001).
Insertive and receptive anal sex in the last 12 months
were reported by 143 (71.5 %) and 140 (70.0 %) partici-
pants, respectively. Among MSMW, insertive anal sex
was more commonly practised than receptive anal sex
(86.5 % vs 33.3 %), while MSM only reported more
receptive anal sex than insertive anal sex (80.6 % vs
67.1 %). Compared to MSM only, significantly more
MSMW practised insertive anal sex (p = 0.010) and less
receptive anal sex (p < 0.001). MSM only participants
practised significantly more receptive oral sex (95.5 % vs
57.8 %) and insertive oro-anal sex (43.2 % vs 22.2 %) in
the last 12 months. The SPM analysis revealed that 36
(80.0 %) MSMW participants had a female partner
among their last 10 sexual partners. Performing vaginal
intercourse was reported by 34 (94.4 %) of these MSMW
participants, performing anal sex on women was less
common (15/36; 41.7 %), while performing and receiv-
ing oral sex with women was reported by 29 (80.6 %)
and 22 (61.1 %) participants, respectively. Performing
and receiving oro-anal sex with women was only
reported by 7/36 (19.4 %) participants.
HIV and STI prevalence
As previously reported, 47 (23.5 %) participants reported
having an STI diagnosis within the previous year, mostly
with a single STI episode (80.9 % of cases) [17]. Eighty
eight (44.0 %) participants were HIV positive with the
majority (74.1 %) having CD4 counts below 500 cells/μl.
Twenty two (11.0 %) participants tested positive for
syphilis antibodies. Neisseria gonorrhoeae and Chlamydia
trachomatis infections were detected in 32 (16 %) and 23
(11.5 %) MSM, respectively.
HPV prevalence and genotype distribution
As shown in Tables 2 and 3, a total of 191 anal swabs
(95.5 %), 200 oro-pharyngeal swabs (100 %) and 190
urines (95 %) had a valid HPV DNA result and were
ncluded in the analysis; test strips lacking human beta
globin DNA detection were reported as invalid. An overall
HPV prevalence of 75 % (150/200) [95 % CI: 68.4–80.8 %]
was observed for all patients, irrespective of the site of
HPV positivity. HPV genotypes were detected in 139/191
(72.8 %) [95 % CI: 65.9–79.0 %], 23/200 (11.5 %) [95 % CI:
7.4–16.8 %] and 29/190 (15.3 %) [95 % CI: 10.5–21.2 %] of
anal, oro-pharyngeal and urine specimens, respectively.
The mean number of HPV types observed in anal, oro-
pharyngeal and urine specimens were 4.47, 1.74 and 1.41
HPV types in HPV-positive MSM, respectively. Multiple
HPV types were observed in 113/191 (59.2 %) [95 % CI:
51.8–66.2 %] of anal specimens, 7/200 (3.5 %) [95 % CI:
1.4–7.1 %] of oro-pharyngeal specimens and 7/190 (3.7 %)
[95 % CI: 1.5–7.4 %] of urine specimens (Fig. 1). The most
HPV types observed in an anal specimen was 15, followed
by 6 HPV types in an oro-pharyngeal specimen and 4
HPV types in a urine specimen.
For anal specimens, a total of 110 (57.6 %) [95 % CI:
50.3–64.7 %] were HR-HPV positive. HR-HPV types
were less prevalent in the pharynx and urine, with 15
(7.5 %) [95 % CI: 4.3–12.1 %] oro-pharyngeal specimens
and 15 (7.9 %) [95 % CI: 4.5–12.7 %] urine specimens
testing positive for HR-HPV. HPV types 16 and 18, the
only HR-HPV types included in both the bivalent and
quadrivalent HPV vaccines, were detected in 55 (28.8 %)
[95 % CI: 22.5–35.8 %] anal specimens, 6 (3.0 %) [95 % CI:
1.1–6.4 %] oro-pharyngeal specimens and 3 (1.6 %) [95 %
CI: 0.3–4.5 %] urine specimens. The prevalence rates of all
HPV genotypes included in the quadrivalent HPV vaccine
(HPV-6/11/16/18) were 77 (40.3 %) [95 % CI: 33.3–
47.6 %], 9 (4.5 %) [95 % CI: 2.1–8.4 %] and 6 (3.2 %) [95 %
CI: 1.2–6.8 %] in anal, oro-pharyngeal and urine samples,
respectively. HPV types included in the new 9-valent HPV
vaccine (HPV-6/11/16/18/31/33/45/52/58) were detected
in 110 (57.6 %) [95 % CI: 50.3–64.7 %], 12 (6.0 %) [95 %
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CI: 3.1–10.3 %] and 10 (5.3 %) [95%CI: 2.6–9.5 %] anal,
oro-pharyngeal and urine specimens, respectively.
The most common HPV types detected in anal speci-
mens were HPV-16 (42; 22 %), HPV-6 (39; 20.4 %) and
HPV-51 (31; 16.2 %). In oro-pharyngeal specimens, the
most common HPV types detected were HPV-16 (6;
3.0 %), HPV-72 (4; 2.0 %), followed by HPV-35 and HPV-
51 (both 3; 1.5 %). The most prevalent HPV types in urine
were HPV-16, HPV-45, HPV-55, HPV-59, HPV-61, HPV-
62, HPV-66 and HPV-70 (all 3; 1.6 %). The HPV type
specific prevalence rates in anal, oro-pharyngeal and urine
specimens are summarised in Fig. 2.
HPV and HIV co-infections
A total of 88 (44.0 %) participants tested HIV-positive in
this study. Among the 85 HIV-positive participants with
Table 1 Baseline and sexual behavioural characteristics stratified according to men who have sex with men only (MSM only) and
men who have sex with men and women (MSMW)
Variable No. (%) of men p-value
MSM only (n = 155) MSMW (n = 45) Totals (n = 200)
Age [years(IQR)] 33 (26–40) 28 (24–37) 32 (26–39.5) 0.025
Gender
Male 140 (90.3) 45 (100.0) 185 (92.5) 0.030
Transgender 15 (9.7) 0 (0.0) 15 (7.5)
Ethnicity
Black 48 (31.0) 14 (31.1) 62 (31.0) ˂0.001
Coloured 38 (24.5) 25 (55.6) 63 (31.5)
White 65 (41.9) 6 (13.3) 71 (35.5)
Other 4 (2.6) 0 (0.0) 4 (2.0)
Education
Completed high school 122 (78.7) 33 (73.3) 145 (72.5) ˂0.001
Tertiary qualification 73 (47.1) 11 (24.4) 84 (42.0)
Transactional sex
No 112 (72.3) 11 (24.4) 123 (61.5) ˂0.001
Yes, paid money for sex 17 (11.0) 7 (15.6) 24 (12.0)
Yes, received money for sex 21 (13.5) 15 (33.3) 36 (18.0)
Yes, paid and received money for sex 5 (3.2) 12 (26.7) 17 (8.5)
Sex while under the influence of drugs
Yes 73 (47.1) 32 (71.1) 105 (52.5) 0.004
No 82 (52.9) 13 (28.9) 95 (47.5)
HIV serostatus
Positive 81 (52.3) 7 (15.6) 88 (44.0) ˂0.001
Negative 74 (47.7) 38 (84.4) 112 (56.0)
Frequency of insertive anal sex
Yes 104 (67.1) 39 (86.7) 143 (71.5) 0.010
No 51 (32.9) 6 (13.3) 57 (28.5)
Frequency of receptive anal sex
Yes 125 (80.6) 15 (33.3) 140 (70.0) ˂0.001
No 30 (19.4) 30 (66.7) 60 (30.0)
Frequency of receptive oral sex
Yes 148 (95.5) 26 (57.8) 174 (87.0) ˂0.001
No 7 (4.5) 19 (42.2) 26 (13.0)
Performing oro-anal sex (rimming)
Yes 67 (43.2) 10 (22.2) 77 (38.9) 0.011
No 88 (56.8) 35 (77.8) 123 (61.5)
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valid anal HPV results, 78 (91.8 %) were co-infected with
any anal HPV (p < 0.001), 73 (85.9 %) had multiple anal
HPV types (p < 0.001), 76 (89.4 %) had LR-HPV (p < 0.001)
and 69 (81.2 %) were co-infected with HR-HPV (p < 0.001)
(Table 2). Quadrivalent HPV vaccine types 6, 11, 16
and 18 were detected in 47 (55.3 %) anal specimens
of HIV-positive participants (p < 0.001), and increased
to 62 (72.9 %) with the addition of cross-protection
HPV types 31, 33 and 45 (p < 0.001). Having any oro-
pharyngeal HPV infection (15/88; 17.1 %) and having
a LR-HPV oro-pharyngeal infection (10/88; 11.4 %)
were significantly associated with being HIV-positive
(p = 0.029 and p = 0.032 respectively). Multiple anal HPV
types were detected more frequently in HIV-positive
MSM (85.9 % vs 37.7 % in HIV-negative MSM). The mean
number of HPV types detected in HPV-positive anal sam-
ples was 5.7 (range 1–15) in HIV-positive participants and
2.9 (range 1–10) in HIV-negative participants (p < 0.001).
HPV according to sex partner status
Significant differences in anal HPV prevalence were ob-
served between men who had sex with men only (MSM
only) and men who had sex with men and women
(MSMW) (Table 3). MSMW were less likely to have any
Table 2 HPV and HIV-co-infection at 3 anatomical sites among MSM in Cape Town, South Africa
HPV type
classification














No type 52 (27.2) 45 (42.4) 7 (8.2) ˂0.001 177 (88.5) 104 (92.9) 73 (83.0) 0.029 161 (84.7) 91 (85.1) 70 (84.3) 0.892
Any type 139 (72.8) 61 (57.6) 78 (91.8) ˂0.001 23 (11.5) 8 (7.1) 15 (17.1) 0.029 29 (15.3) 16 (14.3) 13 (14.8) 0.892
Single type 26 (13.6) 21 (19.8) 5 (5.9) 0.005 16 (8.0) 6 (5.4) 10 (11.4) 0.120 22 (11.6) 14 (12.5) 8 (9.1) 0.461
Multiple
types
113 (59.2) 40 (37.7) 73 (85.9) ˂0.001 7 (3.5) 2 (1.8) 5 (5.7) 0.136 7 (3.7) 2 (1.8) 5 (5.7) 0.131
LR-HPV 126 (66.0) 50 (47.2) 76 (89.4) ˂0.001 14 (7.0) 4 (3.6) 10 (11.4) 0.032 19 (10.0) 8 (7.5) 11 (13.3) 0.188
HR-HPV 110 (57.6) 41 (38.7) 69 (81.2) ˂0.001 15 (7.5) 6 (5.4) 9 (10.2) 0.194 15 (7.9) 9 (8.4) 6 (7.2) 0.764
HPV-6/11 50 (26.2) 19 (17.9) 31 (36.5) 0.003 3 (1.5) 1 (0.9) 2 (2.3) 0.425 3 (1.6) 0 (0.0) 3 (3.6) 0.047
HPV-16/18 55 (28.8) 19 (17.9) 36 (42.4) ˂0.001 6 (3.0) 3 (2.7) 3 (3.4) 0.763 3 (1.6) 2 (1.9) 1 (1.2) 0.715
HPV-6/11
/16/18
77 (40.3) 30 (28.3) 47 (55.3) ˂0.001 9 (4.5) 4 (3.6) 5 (5.7) 0.474 6 (3.2) 2 (1.9) 4 (4.8) 0.248
HPV-31
/33/45
50 (26.2) 14 (13.2) 36 (42.4) ˂0.001 3 (1.5) 0 (0.0) 3 (3.4) 0.048 5 (2.6) 3 (2.8) 2 (2.4) 0.866
HPV-6/11/16
/18/31/33/45
98 (51.3) 36 (34.0) 62 (72.9) ˂0.001 11 (5.5) 4 (3.6) 7 (8.0) 0.177 10 (5.3) 5 (4.7) 5 (6.0) 0.679
Table 3 HPV infection among MSM only and MSMW at 3 anatomical sites among MSM in Cape Town, South Africa
HPV type
classification
ANAL (n = 191) ORO-PHARYNGEAL (n = 200) URINE (n = 190)













No type 52 (27.2) 22 (14.8) 30 (73.2) <0.001 177 (88.5) 133 (85.8) 44 (97.8) 0.027 161 (84.7) 123 (84.8) 38 (84.4) 0.950
Any type 139 (72.8) 128 (85.3) 11 (26.8) <0.001 23 (11.5) 22 (14.2) 1 (2.2) 0.027 29 (15.3) 22 (15.2) 7 (15.6) 0.950
Single type 26 (13.6) 22 (14.7) 4 (9.8) 0.416 16 (8.0) 15 (9.7) 1 (2.2) 0.105 22 (11.6) 18 (12.4) 4 (8.9) 0.519
Multiple
types
113 (59.2) 106 (70.7) 7 (17.1) <0.001 7 (3.5) 7 (4.5) 0 (0.0) 0.147 7 (3.7) 4 (2.8) 3 (6.7) 0.224
LR-HPV 126 (66.0) 117 (78.0) 9 (22.0) <0.001 14 (7.0) 13 (8.4) 1 (2.2) 0.154 19 (10.0) 15 (10.3) 4 (8.9) 0.776
HR-HPV 110 (57.6) 102 (68.0) 8 (19.50 <0.001 15 (7.5) 15 (9.7) 0 (0.0) 0.030 15 (7.9) 10 (6.9) 5 (11.1) 0.359
HPV-6/11 50 (26.2) 48 (32.0) 2 (4.9) <0.001 3 (1.5) 3 (1.9) 0 (0.0) 0.347 3 (1.6) 3 (2.1) 0 (0.0) 0.331
HPV-16/18 55 (28.8) 52 (34.7) 3 (7.3) <0.001 6 (3.0) 6 (3.9) 0 (0.0) 0.180 3 (1.6) 2 (1.4) 1 (2.2) 0.692
HPV-6/11
/16/18
77 (40.3) 73 (48.7) 4 (9.8) <0.001 9 (4.5) 9 (5.8) 0 (0.0) 0.098 6 (3.2) 5 (3.5) 1 (2.2) 0.681
HPV-31
/33/45
50 (26.2) 48 (32.0) 2 (4.9) <0.001 3 (1.5) 3 (1.9) 0 (0.0) 0.347 5 (2.6) 2 (1.4) 3 (6.7) 0.053
HPV-6/11/16
/18/31/33/45
98 (51.3) 94 (62.7) 4 (9.8) <0.001 11 (5.5) 11 (7.1) 0 (0.0) 0.066 10 (5.3) 6 (4.1) 4 (8.9) 0.212
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anal HPV (85.3 % vs.26.8 %; p < 0.001), multiple anal
HPV (70.7 % vs. 17.1 %; p < 0.001), anal LR-HPV (78.0 %
vs. 22.0 %; p < 0.001), anal HR-HPV (68.0 % vs.
19.5 %; p < 0.001), anal HPV-6/11/16/18 (48.7 % vs.
9.8 %; p < 0.001) and anal HPV-6/11/16/18/31/33/45
(62.7 % vs. 9.8 %; p < 0.001). Individuals who had sex
with men only were more likely to have any oro-
pharyngeal HPV infection (14.2 % vs. 2.2 %; p = 0.027) and
to have an oro-pharyngeal HR-HPV infection (9.7 % vs
0.0 %; p = 0.030). No significant differences were observed
between MSM only and MSMW with regards to the
prevalence of HPV in urine specimens.
Risk factors associated with HPV infections
Univariate and multiple logistic regression analyses were
performed to assess potential and independent associa-
tions between participant characteristics/sexual risk fac-
tors and HPV infection in this population (Table 4). In
univariate analysis having any anal HPV infection was sig-
nificantly associated with receiving an income (p = 0.044),
having sex with men only (p < 0.001), engaging in group
sex in their lifetime (p = 0.002), being HIV positive
(p < 0.001) and practising receptive anal sex (p < 0.001).
Having a HR-HPV infection in the anal canal was signifi-
cantly associated with living outside the city (p = 0.050),
transgender identity (p = 0.031), having sex with men
only (p < 0.001), engaging in group sex in their lifetime
(p = 0.006), sharing sex toys in last year (p = 0.042),
being HIV positive (p < 0.001), practising receptive anal
sex (p < 0.001) and having a gonococcal co-infection
(p = 0.043). Multiple anal HPV infections were de-
tected more frequently in participants that identified
as transgender (p = 0.022), having sex with men only
(p < 0.001), being HIV positive (p < 0.001), practising
receptive anal sex (p < 0.001) and having a gonococcal
co-infection (p = 0.028). Compared to other ethnicities,
coloured MSM had significantly less anal HPV infections
overall (p = 0.023), including HR-HPV (p = 0.003) and
multiple HPV types (p = 0.013). Individuals who par-
ticipated in transactional sex had fewer multiple anal HPV
infections (p = 0.010). In multiple logistic regression
analyses, having sex with men only (AOR: 10.9, 95 % CI:
Fig. 1 Number of HPV types in anal, oro-pharyngeal and urine specimens obtained from MSM participants in Cape Town
Fig. 2 HPV type-specific prevalence rates in anal, oro-pharyngeal and urine specimens obtained from MSM participants in Cape Town
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Table 4 Univariate and multivariate logistic regression analyses for factors associated with any-, high-risk and multiple anal HPV infections















Male 124 (89.2) Ref 97 (88.2) Ref 99 (87.6) Ref
Transgender
(MTF)
15 (10.8) 1.0 13 (11.8) 5.3
(1.16–24.16)




Black 46 (33.1) Ref Ref 40 (36.4) Ref Ref 39 (34.5) Ref
Coloured 35 (25.2) 0.4
(0.18–0.88)




0.042 26 (23.0) 0.4
(0.19–0.82)
0.013
White 55 (39.6) 1.2
(0.50–2.83)




0.219 47 (41.6) 1.2
(0.54–2.42)
0.717
Other 3 (2.2) 0.9
(0.08–8.85)








City/suburbs 96 (69.1) Ref 73 (66.4) Ref 76 (67.3) Ref
Informal
settlement
33 (23.7) 1.6 (0.72–3.73) 0.236 28 (25.5) 1.8
(0.88–3.73)
0.108 28 (24.8) 1.7
(0.80–3.42)
0.171
Outside city 10 (7.2) 1.0 9 (8.2) 8.1
(1.00–65.96)




No income 24 (17.3) Ref 18 (16.4) Ref 20 (17.7) Ref
Income 115 (82.7) 2.1
(1.02–4.44)
0.044 92 (83.6) 1.9
(0.94–3.85)







11 (2.9) Ref Ref 8 (7.3) Ref Ref 7 (6.2) Ref Ref
Men only 128 (92.1) 15.9
(6.95–36.24)









Engaged in group sex in lifetime















Table 4 Univariate and multivariate logistic regression analyses for factors associated with any-, high-risk and multiple anal HPV infections (Continued)
Shared sex toys in past 12 months
No 111 (79.9) Ref 85 (77.3) Ref 88 (77.9) Ref
Yes 28 (20.1) 1.9
(0.75–4.98)
0.172 25 (22.7) 2.4
(1.03–5.36)









0.072 36 (32.7) 0.6
(0.34–1.10)




Negative 61 (43.9) Ref Ref 41 (37.3) Ref Ref 40 (35.4) Ref Ref
Positive 78 (56.1) 8.2
(3.46–19.50)









Receptive anal intercourse with men
Never practised 24 (17.3) Ref 14 (12.7) Ref Ref 14 (12.4) Ref Ref
Practised 115 (82.7) 7.7
(3.77–15.61)










Negative 125 (89.9) Ref 98 (89.1) Ref 100 (88.5) Ref
Positive 14 (10.1) 1.0 12 (10.9) 4.8
(1.05–22.25)
















3.88–30.81, p < 0.001), engaging in group sex in lifetime
(AOR: 4.7, 95 % CI: 1.79–12.43, p = 0.002), being HIV-
positive (AOR: 4.1, 95 % CI: 1.52–11.22, p = 0.006) and
practising receptive anal intercourse (AOR: 3.3, 95 % CI:
1.36–8.09, p = 0.009) were the only factors associated with
having any anal HPV infection after adjusting for con-
founders and other variables found significant in the uni-
variate analysis. Coloured ethnicity was associated with
significantly less anal HR-HPV infections (AOR: 0.4, 95 %
CI: 0.13–0.96, p = 0.042) while having sex with men only
(AOR: 4.6, 95 % CI: 1.63–12.74, p = 0.005), engaging
in group sex in lifetime (AOR: 3.1, 95 % CI: 1.35–
7.07, p = 0.006), being HIV-positive (AOR: 4.1, 95 %
CI: 1.89–8.83, p < 0.001) and practicing receptive anal
intercourse (AOR: 4.3, 95 % CI: 1.80–10.13, p < 0.001)
were all associated with having a greater likelihood of
infection by a HR-HPV type. Having multiple anal
HPV infections were independently associated with
having sex with men only (AOR: 5.5, 95 % CI: 1.92–
15.51, p = 0.001), being HIV-positive (AOR: 6.9, 95 %
CI: 3.10–15.42, p < 0.001) and practising receptive anal
intercourse (AOR: 4.2, 95 % CI: 1.79–9.65, p = 0.001).
Age group, education, job status, partner status, number of
male sexual partners in the past 12 months, sex at sex-on-
site venues, sex with a partner met through the internet,
engaging in group sex in the past 12 months, alcohol
and drug use during sex, having had a STI in the
past 12 months, syphilis serostatus and having an anal
chlamydial infection were not significantly associated
with the three HPV outcomes in the anal canal. Fur-
ther, no risk factors were independently associated
with oro-pharyngeal HPV infections or with HPV de-
tected in the urine.
Discussion
This study reports HPV prevalence and risk factors asso-
ciated with HPV infections at three different anatomical
sites among high-risk MSM in Cape Town. We found a
high prevalence of HR-HPV (57.6 %) in the anal canal of
study participants. HPV genotypes were less frequently
detected in the pharynx (11.5 %) and urine (15.3 %) of
study participants. Previous studies have shown that anal
HPV infection is more common among MSM than
heterosexual men (MSW), and that anal HPV prevalence
rates can be 4–10 times higher in MSM compared to
MSW [19, 20]. The high prevalence of anal HPV infec-
tion observed in this study is similar to anal HPV
prevalence rates for high-risk MSM reported in Peru,
Italy and Thailand but higher than anal HPV preva-
lence rates reported in countries such as Australia and
Puerto Rico [9, 21–24].
MSM who are HIV-positive have an increased risk of
anal HPV infection and anal cancer. HPV prevalence
rates of 89–93 % have been reported among HIV-
positive MSM in a recent systematic review and meta-
analysis of 53 studies [7]. The incidence of anal cancer
among HIV-positive MSM is more than 80-fold higher
than that observed in the general population [25]. HIV
infection has been shown to increase susceptibility to
persistent HPV, increasing the risk of acquiring new
HPV infections and reactivation of latent HPV infections
[12]. Persons who are at high risk for HIV acquisition
may be at higher risk of HPV infection due to the same
high risk sexual practises [11]. As shown in Table 2,
HIV-positive MSM had significantly more anal HPV
infections overall (91.8 % HIV-infected vs. 57.6 % HIV-
uninfected), including LR-HPV, HR-HPV, multiple HPV
types and HPV vaccine types (HPV-6/11/16/18 + 31/33/45).
The most common LR-HPV and HR-HPV types detected
in the anal specimens of all MSM as well as HIV-positive
MSM were HPV-6 and HPV-16 respectively, followed
by high risk types HPV-58, HPV-45 and HPV-51. HPV-
16 was also the most common HR-HPV type found in
HIV-positive MSM from Thailand, USA, China, Spain
and Canada [9, 12, 26–28].
Multiple anal HPV infections are commonly described
among MSM, especially HIV-positive MSM [8, 26–28].
Having more than one HPV type detected was more
common in the anal canal of MSM while single HPV
infections were more frequently detected in the pharynx
and urine. In this study, multiple HPV types were
detected in the anal specimens of 59.2 % of all MSM,
81.3 % of all HPV-positive MSM and 85.9 % of HIV-
positive MSM. Among an HIV-positive MSM cohort in
Canada (HIPVIRG cohort study), the majority of partici-
pants (90.9 %) were infected with multiple HPV types in
the anal canal, ranging between 0 and 18 HPV types
(mean 5 HPV types) [12]. More recently, Supindham et al.
[9] reported a 100 % HPV co-infection rate in the anal
specimens of HIV-positive MSM in Thailand, with the
majority being multiple HPV infections (mean 4.8 HPV
types). The mean number of anal HPV types detected in
HPV-positive MSM in this study was 4.5 types, which in-
creased to 5.7 types among HIV-positive MSM (p < 0.001).
The highest number of HPV types detected in a single
anal sample was 15 HPV types in an HIV-positive partici-
pant co-infected with anal gonorrhoea and chlamydia.
The mean number of HPV types in the oropharynx and
urine was 1.7 and 1.4 types respectively, and the number
of HPV types at these anatomical sites did not differ signifi-
cantly according to HIV status. Multiple anal HPV infec-
tions are a cause for concern due to the strong association
with anal intraepithelial neoplasia (AIN) and the develop-
ment to high-grade AIN and anal cancer [29, 30].
Oro-pharyngeal HPV infections are much less common
in adults than anogenital HPV infections [31]. King et al.
[14] reported that the majority of HPV infections detected
in the oral cavity of MSM in London were single HPV
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types. However, the incidence of HPV-related oro-
pharyngeal cancers in the general population is increasing
relative to other oral cancers associated with alcohol and
tobacco use. A number of HR-HPV types have been impli-
cated in carcinogenesis and tumour progression at differ-
ent anatomical sites and are mainly due to the actions of
their E6 and E7 viral oncogenes, which induce and main-
tain cellular transformation [32]. The majority of oro-
pharyngeal squamous cell carcinomas (OPSCC) (+ − 90 %
of cases) are associated with HPV-16 infection; however
other HR-HPV types have also been identified in HPV-
positive OPSCC and these types, although rare, constitute
an important subset of oro-pharyngeal cancers which
should not be ignored [33]. A few studies have reported
associations between non-HPV-16 high-risk types and
oro-pharyngeal cancer after controlling for or excluding
HPV-16 infection [34–36]. A large US case–control study
demonstrated that combined infections with HPV-16 and
other HR-HPV types significantly increased the risk of
head and neck squamous cell carcinoma [36]. Further
studies are needed to determine whether oro-pharyngeal
tumours containing non-HPV-16 high-risk types present
less often with lymph node metastases and have better
treatment outcomes [33, 37]. Davidson et al [38] reported
a HPV prevalence of 5.6 % in oral rinse and gargle samples
among male factory workers in Pretoria, South Africa,
aged 17 - 64 years. Although oral sex was not common in
this population, it was practised among men identified
with HR-HPV infection [38]. Performing oral and oro-
anal sex on men and women were not associated with
oro-pharyngeal HPV infections in this study. However,
HIV-positive MSM had significantly more oro-pharyngeal
HPV infections (17.1 % in HIV-positive vs. 7.1 % in HIV-
negative; p = 0.029), including LR-HPV infections (11.4 %
in HIV-positive vs. 3.6 % in HIV-negative; p = 0.032). It is
not clear if the increased oral HPV incidence in HIV-
positive individuals is due to HIV-related immunosup-
pression or due to risky sexual practises [39]. In Italy,
Parisi et al. [40] detected HPV in the oral specimens of
approximately 20 % of HIV-infected MSM, which is lower
than that reported by Blas et al. [41] (44.3 %) in Peru, but
higher than the oro-pharyngeal HPV prevalence rates in
HIV-positive MSM reported in this study. In our study,
having any HPV infection or a LR-HPV infection in the
oropharynx were the only oro-pharyngeal HPV groupings
associated with being HIV-positive. No differences were
observed between HIV-negative and HIV-positive MSM
with regards to the prevalence of single HPV types, mul-
tiple HPV types, HR-HPV or HPV vaccine types detected
in the oropharynx.
This study showed that MSM only had over three
times more anal HPV infections and over 6 times more
oro-pharyngeal HPV infections than MSMW. Anal HPV
prevalence rates among MSM only were significantly
higher for all HPV groupings, except for single HPV type
prevalence. Having any oro-pharyngeal HPV infection or
an oro-pharyngeal HR-HPV infection were the only oro-
pharyngeal HPV groupings that showed significant dif-
ferences between MSM only and MSMW. No significant
differences were observed in the prevalence of HPV in
urine between MSM only and MSMW. Compared to
other male populations higher anal HPV prevalence
rates are frequently reported for MSM only [19, 24, 42].
Limited information is available in the literature describ-
ing HPV prevalence rates in MSMW, especially anal
HPV prevalence rates. Lu et al. [43] studied the sero-
prevalence of quadrivalent HPV vaccine types (HPV-
6,11,16,18) among men with different sexual practises in
Brazil, Mexico and USA (The HIM study) and found
MSMW to have lower HPV seroprevalence rates than
MSM but higher than in MSW. Genital HPV prevalence
analysis in the same HIM study cohort showed that
MSMW had higher HPV prevalence rates on the penis
and scrotum compared to MSM and MSW, which could
be attributed to increased number of sex partners and
increased frequency of insertive sex acts among MSMW.
In our study, in comparison with the MSM only group,
significantly fewer MSMW were HIV-positive, practised
receptive anal intercourse with men whilst more MSMW
practised insertive anal intercourse with men. These sex-
ual practises could account for the absence of gonococcal
and chlamydial co-infections detected in the anal canal of
MSMW and the increased number of chlamydial co-
infections detected in the urine of MSMW. MSMW were
also less likely to be syphilis seropositive. Even though anal
HPV infection among MSMW who practise receptive anal
intercourse could be linked to these sexual practises, anal
HPV transmission can also be attributed to other factors,
similar to those found among HPV-infected MSW, such
as transmission through skin contact, sharing sex toys or
vertical transmission. Genital HPV genotypes have been
detected on fingers and HPV transmission between ano-
genital sites and hands have previously been reported
among heterosexual couples [44]. These alternative modes
of HPV transmission could explain the observation that
17.3 % of men who indicated no history of receptive anal
intercourse had HPV detected in the anal canal.
This study had a number of limitations. Firstly, the
relatively small sample size may have resulted in the
misidentification of some predictors of HPV infection,
especially in oro-pharyngeal and urine samples where
the prevalence of HPV was low. Secondly, the liquid oral
rinse sampling method has been shown to have a higher
sensitivity than oro-pharyngeal swabs for the detection
of HPV in the mouth and throat and therefore the use
of oro-pharyngeal swabs in this study could have de-
creased the HPV detection rate in the oropharynx [13].
Thirdly, we were only able to test DNA extracts from
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urine as an indicator of urethral HPV infection. This
was due to the sampling undertaken in the primary
study; the true prevalence of penile HPV may have been
higher than that reported here if penile samples had also
been available for additional HPV testing. Fourthly, the
participants attended one clinic in Cape Town and the
findings of this study might not be generalized to the
South African MSM population.
In keeping with South Africa’s National Strategic
Plan for HIV and AIDS, STIs and TB, scaling up ser-
vices for most at risk populations (including MSM) to
reduce HIV/STI burden should be prioritised. For
HPV, these efforts include targeted behavioural inter-
ventions such as promotion of proper and consistent
condom use, medical male circumcision to reduce the
incidence, prevalence and persistence of HPV in-
fections in MSM and HPV vaccination of boys. The
South African government is currently providing free
HPV vaccinations for 9–10 year old girls in all public
schools in South Africa but it is unlikely that MSM
would benefit from herd immunity due to female
vaccination roll-out and it would be optimal to vaccin-
ate boys directly. Randomised controlled trials have
shown HPV vaccination to be highly efficacious in
MSM with the potential to substantially reduce the
burden of HPV-associated disease in this population
[45]. More studies are needed to determine the natural
history and burden of HPV-associated diseases in South
African MSM in order to formulate effective HPV preven-
tion strategies for the future.
Conclusions
A high prevalence of anal HPV infection was observed
in this MSM population in Cape Town. All HPV group-
ings (any HPV, LR-HPV, HR-HPV, single type, multiple
type, quadrivalent vaccine types) were more prevalent in
the anal canal of HIV-positive MSM. Risk factors associ-
ated with any HPV, HR-HPV and multiple HPV types in
the anal canal included having sex with men only, being
HIV-positive and practising receptive anal intercourse.
No risk factors were independently associated with oro-
pharyngeal HPV infection or HPV detected in urine.
Targeted interventions and HPV vaccination of boys
should be considered to reduce the burden of HPV-
related diseases among MSM in South Africa.
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